Major Trends and Emerging Patterns in the Age-Related Macular Degeneration Market: Innovative Treatments for Age-Related Macular Degeneration: Focus on Bispecific Antibodies
Discover trends, market shifts, and competitive outlooks for the age-related macular degeneration industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Projected CAGR for the Age-Related Macular Degeneration Market Size from 2025 to 2034?
In recent times, the market for age-related macular degeneration has seen a significant increase in size. The market, which is projected to rise from $9.96 billion in 2024, is expected to hit $10.7 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.5%. The surge in growth during the historic period can be linked to the aging population, changes in lifestyle, environmental contributors, genetic risks, heightened consciousness, early detection, and improvements in diagnostic methods.
The market for age-related macular degeneration is anticipated to witness robust expansion in the coming years, expanding to an impressive “$14.38 billion by 2029 with a compound annual growth rate (CAGR) of 7.7%. Contributions to the growth during the forecast period are expected to come from continued investigation in genetics and biomarkers, burgeoning therapeutic methods, telemedicine and remote patient monitoring, and efforts towards patient advocacy and education. Key trends for the forecast period include tailored medicine approaches, advances in retinal image technology, the emergence of lasting drug delivery systems, clinical trials examining new therapies, and partnership efforts aimed at research and development.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Age-Related Macular Degeneration Market?
The anticipated increase in cases of age-related macular degeneration (AMD) is predicted to stimulate the growth of the AMD market. AMD is an escalating eye illness that impacts the macula, which is a small region of the retina accountable for central vision. Treatments for AMD provide assistance to patients dealing with retinal disorders, mitigating the harshness of the illness. For example, reports from Optimaxa, a UK-based specialist in laser eye treatment, revealed that AMD affected about 196 million people worldwide in February 2023. This number is projected to rise to 288 million by 2040, making up 8.7 percent of the global population. Consequently, the upsurge in AMD occurrence is catalyzing the expansion of the AMD market.
Which Primary Segments of the Age-Related Macular Degeneration Market Are Driving Growth and Industry Transformations?
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Products
3) By Route Of Administration: Intravenous, Intravitreal
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=10845&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Age-Related Macular Degeneration Market?# Market?
North America was the largest region in the global age-related macular degeneration market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Most Significant Market Trends in the Age-Related Macular Degeneration Market?
Leading corporations within the age-related macular degeneration (AMD) industry are pioneering novel treatment options, including bispecific antibodies, designed to minimize treatment cycles. Bispecific antibodies are specially programmed antibodies with the ability to attach to two distinct antigens at the same time. For example, Chugai Pharmaceutical Co., Ltd., a pharmaceutical firm situated in Japan, introduced Vabysmo intravitreal injection 120 mg/mL in May 2022. This innovative bispecific antibody is intended to manage eye disorders such as AMD and diabetic macular edema (DME). The transformative treatment works by concurrently focusing on two crucial pathways: angiopoietin-2 (Ang-2), known to drive irregular blood vessel growth and inflammation, and Vascular Endothelial Growth Factor-A (VEGF-A), an influential agent in the development of new blood vessels potentially causing vision impairment. One prime advantage of Vabysmo is its prolonged dosing windows, allowing for treatments every 16 weeks, thus improving treatment adherence and patient comfort. Its dual-targeting strategy signifies a crucial advancement in eye care treatments, effectively addressing the demand for effective therapies for retinal diseases.
View the full report here:
What Parameters Are Used to Define the Age-Related Macular Degeneration Market?
Age-related macular degeneration (AMD) refers to a progressive eye condition in which the macula, which is located at the center of the retina, deteriorates over time in individuals with AMD, leading to a decline in central vision. It is due to aging. The therapy options for age-related macular degeneration include regular eye exams, lifestyle changes, and particular nutritional supplements.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10845
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
